Field comparison of OraQuick® ADVANCE Rapid HIV-1/2 antibody test and two blood-based rapid HIV antibody tests in Zambia by unknown
RESEARCH ARTICLE Open Access
Field comparison of OraQuickW ADVANCE Rapid
HIV-1/2 antibody test and two blood-based rapid
HIV antibody tests in Zambia
Dalila Zachary1,2*, Lawrence Mwenge1, Monde Muyoyeta1,3, Kwame Shanaube1,3, Albertus Schaap1,2,
Virginia Bond1,4, Barry Kosloff1,3, Petra de Haas1,3 and Helen Ayles1,3
Abstract
Background: Zambia’s national HIV testing algorithm specifies use of two rapid blood based antibody assays,
DetermineWHIV-1/2 (Inverness Medical) and if positive then Uni-GoldTM Recombigen HIV-1/2 (Trinity Biotech). Little
is known about the performance of oral fluid based HIV testing in Zambia. The aims of this study are two-fold: 1) to
compare the diagnostic accuracy (sensitivity and specificity) under field conditions of the OraQuickW ADVANCEW
Rapid HIV-1/2 (OraSure Technologies, Inc.) to two blood-based rapid antibody tests currently in use in the Zambia
National Algorithm, and 2) to perform a cost analysis of large-scale field testing employing the OraQuickW.
Methods: This was a operational retrospective research of HIV testing and questionnaire data collected in 2010 as
part of the ZAMSTAR (Zambia South Africa TB and AIDS reduction) study. Randomly sampled individuals in twelve
communities were tested consecutively with OraQuickW test using oral fluid versus two blood-based rapid HIV tests,
DetermineW and Uni-GoldTM. A cost analysis of four algorithms from health systems perspective were performed: 1)
DetermineW and if positive, then Uni-GoldTM (DetermineW/Uni-GoldTM); based on current algorithm, 2) DetermineW
and if positive, then OraQuickW (DetermineW/OraQuickW), 3) OraQuickW and if positive, then DetermineW
(OraQuickW/DetermineW), 4) OraQuickW and if positive, then Uni-GoldTM (OraQuickW/Uni-GoldTM). This information
was then used to construct a model using a hypothetical population of 5,000 persons with varying prevalence of
HIV infection from 1–30%.
Results: 4,458 participants received both a DetermineW and OraQuickW test. The sensitivity and specificity of the
OraQuickW test were 98.7 (95%CI, 97.5–99.4) and 99.8 (95%CI, 99.6–99.9), respectively when compared to HIV
positive serostatus. The average unit costs per algorithm were US$3.76, US$4.03, US$7.35, and US$7.67 for
DetermineW/Uni-GoldTM, DetermineW/OraQuickW, OraQuickW/DetermineW, and OraQuickW/Uni-GoldTM, respectively,
for an HIV prevalence of 15%.
Conclusions: An alternative HIV testing algorithm could include OraQuickW test which had a high sensitivity and
specificity. The current DetermineW/Uni-GoldTM testing algorithm is the least expensive when compared to
DetermineW/OraQuickW, OraQuickW/DetermineW, and OraQuickW/Uni-GoldTM in the Zambian setting. From our field
experience, oral fluid based testing offers many advantages over blood-based testing, especially with self testing on
the horizon.
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Background
The introduction of rapid HIV antibody tests has revolu-
tionized HIV diagnosis by facilitating the testing of mil-
lions of people worldwide. The availability of affordable,
point-of-service HIV testing is especially important in
low-income, high-HIV-burden countries which lack the
financial and technological resources to perform more
sophisticated laboratory-based assays. For these reasons,
blood based rapid HIV tests have become the standard
of care and the basis for the national HIV testing algo-
rithm in many developing countries, including Zambia
[1-3].
Zambia’s HIV prevalence of 13.5% [4] makes HIV
testing a national health priority and the national HIV
testing algorithm specifies sequential blood-based rapid
antibody tests: first DetermineWHIV-1/2 Antibody (In-
verness Medical) is used, which if reactive is followed
by a different antibody test, Uni-GoldTM Recombigen
HIV-1/2 Antibody (Trinity Biotech). If the screening
and confirmatory tests yield discordant results, then a
third blood-based rapid antibody test, BiolineW HIV-1/2
test (Standard Diagnostic), is performed or blood is
sent for enzyme linked immunosorbent assay (ELISA)
testing [1].
Despite the benefits of HIV testing, a majority of
patients living in developing countries are unaware of
their status. Nine countries, seven of which were in sub-
Saharan Africa (Democratic Republic of Congo, Kenya,
Liberia, South Africa, Swaziland, Tanzania, Zambia),
conducted population-based surveys during 2007 and
2008 and reported HIV testing rates. Collectively, these
seven countries account for 32% of the people living
with HIV globally and 45% of those in sub- Saharan
Africa. Among the seven countries in sub-Saharan
Africa, the median HIV testing rates were 30% among
women and 17% among men. In Zambia, 64.7% of
women and 79.2% of men reported never having an HIV
test [5–9]. In Zimbabwe, inconvenience of testing loca-
tion and testing hours were reported as the main rea-
sons for individuals not accessing voluntary counseling
and testing (VCT) services [10]. These data underscore
the challenges of implementing HIV testing and preven-
tion that are broadly available and accessible in develop-
ing countries and furthermore suggest the need for
innovations in this field.
As useful as blood-based rapid HIV tests have
proven to be, it may be possible to further expand
and improve HIV testing services by employing rapid
tests using oral fluid. Both oral fluid based and blood
based rapid HIV tests are performed manually and
visually read; however, oral fluid-based HIV tests offer
several advantages over blood based assays: oral fluid
collection is less invasive as it does not require blood
draw or finger stick, can be used to self test and is
less hazardous because oral fluid has a lower trans-
mission risk of HIV compared to blood [11–13]. Add-
itionally, in consideration of oral fluid based testing as
a practical alternative, there are potential cost limita-
tions. There are few studies that address the cost of
oral based testing in the field; however, the slow up-
take of oral HIV testing by resource constrained
countries may be due to the cost per test, which is
higher than most blood based tests [14]. Moreover,
oral fluid based HIV testing performance and sensitiv-
ity in the developing countries [15–20] and cross re-
activity with other infections like dengue fever [21]
are still being published.
In this study, we performed a field comparison of
OraQuickW ADVANCE Rapid HIV-1/2 Antibody test
(OraSure Technologies, Inc.) to two blood-based rapid
antibody tests currently in use in the Zambian
National Algorithm for HIV testing. The objectives of
this study were two-fold: 1) to compare the diagnostic
accuracy (sensitivity and specificity) under field condi-
tions of the OraQuickW using oral fluid to two blood-
based rapid antibody tests currently in use in the
Zambia National Algorithm, and 2) to perform a cost
analysis of large-scale field testing employing the
OraQuickW test.
Methods
During 2009 and 2010, the Zambia South Africa TB and
AIDS reduction study (ZAMSTAR) conducted a TB and
HIV prevalence survey among 59,705 randomly sampled
adult residents of sixteen communities in Zambia [22].
The ZAMSTAR study was a community randomized
trial with the main objective of reducing TB and HIV
prevalence by implementing two community level inter-
ventions. Within this larger study, we nested a field
comparison trial of OraQuickW test using oral fluid ver-
sus two blood-based rapid HIV tests, DetermineW and
Uni-GoldTM. Approximately 4,900 OraQuickW tests were
available for use in the field.
Study setting
Of the sixteen ZAMSTAR study communities, twelve
were conveniently sampled to take part in this field com-
parison study. Randomly sampled individuals in twelve
communities in Zambia were tested consecutively from
April 29, 2010 to August 13, 2010 in their homes for
HIV using both the oral fluid and blood-based rapid
assays (Figure 1). All steps in the HIV testing process
(pre-test counseling, sample collection, performance of
assays, interpretation of results, presentation of results
and post-test counseling) were performed in the partici-
pants’ homes by qualified counselors. The twelve
selected sites were mostly urban communities and one
rural community.
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Study enrolment/selection criteria
Participation in this field comparison study was open to
all individuals who met inclusion criteria for the tuber-
culosis prevalence survey. The inclusion criteria for the
tuberculosis prevalence survey were: any person living in
one of the 12 demarcated communities where the study
was taking place, at least 18 years of age, able to give
informed consent and able to provide a sputum sample.
Performing the test
HIV testing was offered by trained HIV counselors.
Specific training on how to use OraQuickW test kit was
offered to 4 team leaders by certified trainers from the
local OraQuickW manufacturing and distributing com-
pany. In the field, 48 counselors were trained on how to
use the OraQuickW test kit by the team leaders.
A questionnaire was administered and then partici-
pants were offered OraQuickW test in parallel to
DetermineW test with an explanation that we were per-
forming a field trial of an HIV test that is not ordinarily
used in our setting (Figure 1). We explained that the in-
formation collected would be useful in informing policy
makers on the performance of the oral based rapid HIV
test and its potential use in the future.
All testing was performed according to the manufac-
turers’ instructions [23-25]. The OraQuickW package
instructions direct the person to place the flat pad above
the teeth against the outer gum. The person gently
swabs around the outer gums, both upper and lower,
one time around, using the flat pad. The person should
not swab the roof of the mouth, the inside of the cheek
or tongue. The flat pad is then inserted into the devel-
oper solution vial and results can be read between 20
and 40 minutes. Counselors were instructed during their
training that they may need to wait longer than 40 min-
utes and that the band may be faint on the OraQuickW
test if the patient was HIV infected and taking antiretro-
viral therapy. Participants who reported HIV infection
prior to testing were not tested using Uni-GoldTM if the
first test (DetermineW or OraQuickW) was positive.
Data collection and analysis
HIV test results were entered immediately into personal
digital assistants (PDA) by the counselor who had per-
formed the test. Participants with a positive DetermineW
and UnigoldTM test were given a referral slip to the local
health facility to access care. Study data, including the
questionnaire were conveyed to the main office in Lu-
saka, where they were downloaded and analyzed using
Stata v. 11 (StataCorp, College Station, TX, USA). All
tests which were recorded as being done within testing
period of April 29, 2010 to August 13, 2010 were
Figure 1 HIV testing algorithm. A If patient self reported Positive HIV status prior to testing then Uni-GoldTM testing was not performed and
patient was referred to local ART clinic. B Patient told about the “window period” and asked to repeat test in 3 months. C Patient was referred for
care at local ART clinic. D Patient was referred for further testing via routine VCT centers.
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included in the analysis. Variables analyzed include base-
line demographics and rapid test results. Measurement
of each tests’ sensitivity and specificity were compared
using X2 test and reported with 95% confidence inter-
vals. Sensitivity of OraQuickW was measured compared
to HIV positive serostatus. HIV positive serostatus was
defined by either having both a positive DetermineW and
Uni-GoldTM test result or a positive DetermineW test re-
sult when the patient self reported a positive HIV seros-
tatus prior to HIV testing.
We performed a cost analysis of four algorithms from
health systems perspective [26]: 1) DetermineW and if posi-
tive, then Uni-GoldTM (DetermineW/Uni-GoldTM); based
on current algorithm, 2) DetermineW and if positive, then
OraQuickW (DetermineW/OraQuickW), 3) OraQuickW and
if positive, then DetermineW (OraQuickW/DetermineW), 4)
OraQuickW and if positive, then Uni-GoldTM (OraQuickW/
Uni-GoldTM). Program costs were retrogressively collected
including personnel for testing and counseling, HIV rapid
test kits, medical and non-medical equipment and supplies,
e.g. gloves, sharps container, lancets, and test kits. Assump-
tions were built into each respective algorithm regarding
the infrastructure and overhead costs. First assumption was
that these tests are done under field conditions, where
counselors perform the test in the client’s home. Second as-
sumption was that operation costs, for example utilities
(electricity and water), space and maintenance, were the
same across all tests. Third assumption was that the set-up
costs were the same for all the tests, e.g., training of HIV
counselors. Cost of an algorithm was estimated based on
the cost of screening a sample on the first rapid HIV assay
and confirmation of a reactive sample on the second rapid
HIV assay. This information was then used to construct a
model using a hypothetical population of 5,000 persons
with varying prevalence of HIV infection from 1–30%. The
published sensitivity and specificity values [23-25] for each
test were used to calculate the number of expected positive
tests for each prevalence category in the model and cost
per algorithm was reported in terms of average cost per
case.
Ethics
This study received ethical approval from the University
of Zambia biomedical research ethics committee.
Results
4,458 participants received both a DetermineW and
OraQuickW test (Figure 2). 3,682 (82.6%) had both a
negative OraQuickW and DetermineW test result. 721
(16.2%) participants had both a positive DetermineW and
OraQuickW test result. The sensitivity and specificity of
the OraQuickW test were 98.7 (95%CI, 97.5–99.4) and
99.8 (95%CI, 99.6–99.9), respectively when compared to
HIV positive serostatus (Table 1).
There were 55 discordant DetermineW and OraQuickW
test results. 40 (73%) were OraQuickW negative and
DetermineW positive and 15 (27%) were OraQuickW
positive and DetermineW negative. A Uni-GoldTM test
should have been performed when either the
DetermineW or OraQuickW tests result were positive, un-
less the participant reported a positive HIV status prior
to testing; however, 31 (56%) Uni-GoldTM test results
were available for the 55 discordant test results. 7 (13%)
reported a positive HIV status prior to testing. Of the 31
Uni-GoldTM test results available for discordant Deter-
mineW and OraQuickW test results, Uni-GoldTM had a
higher agreement rate with OraQuickW test results com-
pared to DetermineW test results. 26 (84%) Uni-GoldTM
and OraQuickW negative test results agreed and 5 (16%)
Uni-GoldTM and DetermineW positive test results agreed.
Female gender was associated with discordant test
results, OR= 2.5, 95%CI: 1.2–5.2. Age, community, HIV
status, and antiretroviral use were not associated with
discordant test results.
When the HIV prevalence is 15%, the average unit
costs per algorithm were US$3.76, US$4.03, US$7.35,
and US$7.67 for DetermineW/Uni-GoldTM, DetermineW/
OraQuickW, OraQuickW/DetermineW, and OraQuickW/
Uni-GoldTM algorithms, respectively. The cost analysis
shows that DetermineW/Uni-GoldTM was the lowest cost
option when compared to the other testing algorithms,
irrespective of the HIV prevalence (Table 2).
Discussion
OraQuickW ADVANCE Rapid HIV-1/2 Antibody test
using oral fluid performed well under field conditions in
Zambia with a sensitivity of 98.7 (95%CI, 97.5–99.4) and
specificity of 99.8 (95%CI, 99.6–99.9). The high sensitiv-
ity and specificity rates in Zambia are comparable to
Pascoe et al. study evaluating OraQuickW in the field
and in rural Zimbabwe [18]. A meta-analysis by Pai
et al., reported a sensitivity of 98.03%[27] for OraQuickW
testing, which is also comparable to our findings.
Not only did OraQuickW perform well under field con-
ditions in Zambia, it also had several notable advantages
over blood based rapid HIV testing such as elimination
of discomfort of a finger prick and reduction of blood
exposure for the health care worker. Anecdotally, many
non-clinical staff found the kits easy to use as well as to
train others to use. The participants were curious about
the new technique, but overall the oral fluid based HIV
testing was widely accepted and did not seem to confuse
participants about the transmission of HIV through oral
secretions; however, a separate study would need to be
performed to address these issues more clearly.
Proper storage of rapid HIV test kits is also essential
to ensure optimal performance. This can be challenging in
climates with extreme temperatures. The manufacturers’
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recommended storage temperatures for the test kits dis-
cussed in this paper are similar: OraQuickW should be stored
at 15°–27°C, Uni-GoldTM should be stored at 2°–27°C,
and DetermineW should be stored at 2°–30°C [23–25].
While these wide temperature ranges simplify storage
and transport at ambient temperatures in mild or mod-
erate climates, they do not preclude the need for air-
conditioned rooms, refrigerators and transport coolers
in hot climates. Our review of the literature did not
find any studies specifically examining the performance
of OraQuickW when stored above 27°C.
Although there are several published studies validating
the OraQuickW test in Africa, there are few studies that
address the cost of oral based rapid HIV testing in the
field. There is one study in Ethiopia which performed a
direct cost comparison between DetermineW, Ora-
QuickW, CapillusW HIV-1/HIV-2 Rapid Test Kit (Trinity
Biotech) and Uni-GoldTM. The authors of this study sug-
gested implementing oral based tests in Ethiopia’s na-
tional algorithm. DetermineW, CapillusW/OraQuickW
(presence/absence of refrigeration) and Uni-GoldTM
were recommended as screening, confirmatory and tie-
breaker tests, respectively [28]. Another study inTanzania
formulated an alternative cost beneficial confirma-
tory HIV rapid testing algorithm[29]. They included
rapid HIV tests according to WHO recommendation cri-
teria of cost per test <US$2. Both the Ethiopian and
Tanzanian studies did not clearly state the costing meth-
ods or show the cost findings. Our study found that
DetermineW/Uni-GoldTM testing algorithm is the most
attractive investment of the four algorithms examined,
followed by DetermineW/OraQuickW algorithm. However,
the DetermineW/OraQuickW algorithm is not ideal practic-
ally because it loses the main advantage of having
OraQuickW as a screening test, which is that it can be used
for self testing. In developed countries, like the United
States, there are more studies looking at cost for oral
based rapid HIV testing. One such survey performed at 35
community clinics in the United States found the mean
cost per rapid test was US$36.68 for HIV-negative clients
and US$44.22 for preliminary-positive clients[30]. The dif-
ference in costs between Zambia and the US is likely
related to increased operational and human resource costs
in the US.
The high sensitivity and specificity of oral fluid based
HIV testing along with its ease of use make it ideal to
Figure 2 OraQuickW and DetermineW testing. A 138 reported HIV positive status prior to testing. B 4 reported HIV positive status prior to
testing. C 3 reported HIV positive status prior to testing.
Table 1 Sensitivity and specificity of OraQuickW test
Compared to HIV infected1, N = 4,391
Sensitivity (95% CI) 98.7% (97.5%–99.4%)
Specificity (95% CI) 99.8% (99.6%–99.9%)
Positive Predictive Value (95%CI) 99.1% (98.1%–99.7%)
Negative Predictive Value (95%CI) 99.8% (99.5%–99.9%)
1HIV infected as defined by both a positive DetermineW and Uni-GoldTM test
result and/or self reported positive status prior to testing with a positive
DetermineW or OraQuickW test result.
Table 2 Average unit cost* of 6 algorithms at various HIV
prevalence rates in a hypothetical population of 5,000
persons
Algorithm Average Cost (US$) at different HIV Prevalence
1% 5% 10% 15% 20% 25% 30%
DetermineW/
Uni-GoldTM
3.28 3.42 3.59 3.76 3.92 4.09 4.26
DetermineW/
OraQuickW/
3.31 3.52 3.77 4.03 4.29 4.55 4.81
OraQuickW/
DetermineW
7.17 7.22 7.29 7.35 7.41 7.48 7.54
OraQuickW/
Uni-GoldTM
7.20 7.33 7.50 7.67 7.83 8.00 8.17
*Unit cost represents the cost screening HIV in each algorithm.
Zachary et al. BMC Infectious Diseases 2012, 12:183 Page 5 of 7
http://www.biomedcentral.com/1471-2334/12/183
use in developing countries. The biggest challenge of in-
tegrating OraQuickW into testing algorithms is its cost.
Ideally the increased cost of the OraQuickW test would
be offset by an increase in the uptake of testing. How-
ever, our cost analysis was not able to model how many
tests could be done and how many more HIV diagnoses
could be made with OraQuickW testing because we
lacked acceptability data regarding the OraQuickW tests.
Moreover, OraQuickW’s acceptability versus blood-based
rapid HIV testing in the literature is scant. There is one
cross sectional study by Choko et al. in Malawi that
showed very high acceptability and accuracy rates among
participants using oral supervised self testing[13]. They
reported that 91.9% of participants opted to self test
after a brief demonstration and the accuracy was 99.2%.
Given the many barriers to HIV testing and with self
testing on the horizon, oral based HIV testing can offer
an acceptable alternative to blood based testing.
In addition to lacking acceptability data, this study was
also limited by partial verification bias; our gold standard
for the diagnosis of HIV infection was two rapid tests,
based upon how HIV is diagnosed in Zambia. For dis-
cordant results, patients did not have a tiebreaker test in
the field, but instead were referred to the local clinic.
We did not have access to ELISA or western blot (WB).
Moreover, antibody based tests like OraQuickW, Deter-
mineW, and Uni-GoldTM have the disadvantage of miss-
ing acute HIV infection, which is a significant limitation
in a high prevalence population. Accuracy may have also
been affected by difficulties reading the tests under field
conditions that would be absent in a more controlled la-
boratory setting. Third, the HIV test results were not
blinded. All HIV tests were performed and interpreted
by same person, which could have introduced incorpor-
ation bias. Knowledge of the first test result may have
influenced how the second test result was interpreted.
Lastly, the test sensitivities used for the cost analysis
were taken from published literature that had used the
tests among high HIV prevalence populations; however,
despite this fact the costing trends were apparent, Deter-
mineW and if positive, then Uni-GoldTM was the least
expensive of the testing algorithms.
The results from this study can still be generalized to
other resource limited settings where HIV screening has
been rolled out. Although test performance may de-
crease under field conditions, our study shows that those
decreases are subtle and are offset by the high seropreva-
lence of HIV in this setting, thereby increasing the posi-
tive predictive value of the OraQuickW test in places like
Zambia. Moreover, a recently published meta-analysis by
Pai et al.[27] shows that the positive predictive value of
OraQuickW test in high prevalence populations (>1%)
was 98.65% versus 88.55% in low prevalence populations
(<1%).
The need for increased HIV testing is apparent, but
the challenges of universal testing carry with it the un-
certainty of universal treatment. While access to anti-
retroviral therapy has revolutionized the face of HIV/
AIDS in many developing countries like Zambia, the ul-
timate question of when to treat is still debatable. As
more studies are needed to answer this question, this
study adds to the growing body of literature that shows
that oral-based HIV rapid testing in Africa can perform
well.
Conclusions
An alternative HIV testing algorithm could include Ora-
QuickW ADVANCE Rapid HIV-1/2 Antibody test which
had a high sensitivity and specificity. The current Deter-
mineW/Uni-GoldTM testing algorithm is the least expensive
when compared to DetermineW/OraQuickW, OraQuickW/
DetermineW and OraQuickW/Uni-GoldTM in the Zambian
setting. From our field experience, oral fluid based testing
offers many advantages over blood-based testing, especially
with self testing on the horizon.
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